-
. You will use human in vitro models, including astrocytes and brain organoids generated from induced pluripotent stem cells (iPSCs) of people with MLC and healthy controls. You will investigate disease
-
medicines in academic settings; requirements for small-scale (“n-of-few”) manufacturing and quality control of advanced therapy medicinal products (ATMPs); patient-reported outcomes relevant to leukodystrophy
-
symptoms develop. Ultimately, the consortium seeks to enable timely lifestyle interventions that help prevent chronic disease rather than treat it. As a PhD candidate, you will become part of a
-
candidate in October/November 2026. Applicants may, where appropriate and in line with the recruitment procedure, also be considered for other POLARIS doctoral candidate positions that better match their
-
deadline is 5 October 2026. We aim to select the final candidate in October/November 2026. Applicants may, where appropriate and in line with the recruitment procedure, also be considered for other POLARIS
-
deadline is 5 October 2026. We aim to select a final candidate in October/November 2026. Applicants may, where appropriate and in line with the recruitment procedure, also be considered for other POLARIS
-
hiring assessment may be part of the procedure. Read here whether that applies to you. If you join us, we ask you for a VOG (Certificate of Good Conduct). Internal candidates will be given priority over
-
hiring test may be part of the procedure. Read here whether that applies to you. If you join us, we ask you for a VOG (Certificate of Good Conduct). Internal candidates will be given priority over